Beclomethasone Dipropionate

DRUG INFORMATION

  ADULT
    - The dose counter should read “120” for QNASL 80 mcg Nasal Aerosol 120-actuation
      product and “60” for QNASL 40 mcg Nasal Aerosol 60-actuation product.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'dosage and
      administration', retrieved 2026-08-29
    - The recommended dose of QNASL 80 mcg Nasal Aerosol in patients 12 years and older
      is 320 mcg per day administered as 2 actuations in each nostril once daily
      (maximum total daily dose of 4 actuations per day).
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) 2.1 Allergic Rhinitis Adults and Adolescents (12 Years of Age and Older):
      The recommended dose of QNASL Nasal Aerosol is 320 mcg per day administered as 2
      actuations in each nostril (QNASL 80 mcg Nasal Aerosol) once daily (maximum total
      daily dose of 4 actuations per day).
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The safety and effectiveness of QNASL Nasal Aerosol in children 4 years and older
      have been established [see Adverse Reactions (6.1) , Clinical Pharmacology (12.3)
      , Clinical Studies (14) ] . The safety and effectiveness of QNASL Nasal Aerosol in
      children younger than 4 years of age have not been established.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'pediatric
      use', retrieved 2026-08-29
    - 2. DOSAGE AND ADMINISTRATION Administer QNASL Nasal Aerosol by the intranasal
      route only. The dose counter should read “120” for QNASL 80 mcg Nasal Aerosol
      120-actuation product and “60” for QNASL 40 mcg Nasal Aerosol 60-actuation
      product. QNASL Nasal Aerosol does not require priming. See accompanying
      illustrated Patient Information and Instructions for Use leaflet for proper use of
      QNASL Nasal Aerosol. QNASL Nasal Aerosol is for intranasal use only.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'dosage and
      administration', retrieved 2026-08-29
    - ( 2.1 ) The recommended dose of QNASL 40 mcg Nasal Aerosol in children aged 4 to
      11 years of age is 80 mcg per day administered as 1 actuation in each nostril once
      daily (maximum total daily dose of 2 actuations per day).
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for beclomethasone dipropionate
      (QNASL), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for beclomethasone dipropionate
      (QNASL), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary There are no adequate and well-controlled studies with QNASL Nasal
      Aerosol or beclomethasone dipropionate in pregnant women.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'pregnancy',
      retrieved 2026-08-29
    - No published studies, including studies of large birth registries, have to date
      related the use of inhaled corticosteroids (ICS) or intranasal corticosteroids to
      any increases in congenital malformations or other adverse perinatal outcomes.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'pregnancy',
      retrieved 2026-08-29
    - Thus, available human data do not establish the presence or absence of
      drug‑associated risk to the fetus.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Impairment of fertility was observed in rats and dogs at oral doses of
      beclomethasone dipropionate corresponding to 500 and 50 times the MRHD for adults
      on a mg/m 2 basis, respectively. [ see Nonclinical Toxicology ( 13.1 ) ].
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'nursing
      mothers', retrieved 2026-08-29
    - There were no effects in fetuses of pregnant rabbits administered a subcutaneous
      dose 0.4 times the MRHD in adults (on a mg/m 2 basis at a maternal dose of 0.006
      mg/kg/day). 8.2 Lactation Risk Summary There are no data available on the presence
      of beclomethasone dipropionate in human milk, the effects on the breastfed child,
      or the effects on milk production.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'use in
      specific populations', retrieved 2026-08-29
    - However, other corticosteroids have been detected in human milk.
      Source: US FDA label for beclomethasone dipropionate (QNASL), section 'use in
      specific populations', retrieved 2026-08-29